NXL — Nexalin Technology Share News
0.000.00%
Last trade - 00:00- $2.03m
- $1.03m
- $0.30m
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 08:03 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Nexalin Technology Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Nexalin Acquires Ai-Integrated Digital Health Platform Behind Halo™ Clarity And Nexalin Neurocare™ Ahead Of Planned FDA Pivotal Trial
Brief: Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment
U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems
U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
Nexalin rises after outlining steps toward FDA filing for Alzheimer’s device
Brief: Nexalin Announces Pivotal Halo™ Clarity Trial
Brief: Nexalin Technology Receives Nasdaq Listing Status Notification
Brief: Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync
Brief: Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync
Brief: Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia
Brief: Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia
Brief: Nexalin’s DIFS Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Brief: Nexalin’s DIFS Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Brief: Nexalin Technology enters second amendment to equity distribution agreement - SEC filing
Brief: Nexalin Technology Announces Additional Positive Clinical Results In Alzheimer’S Disease With Gen-2 Sync Neurostimulation Device
Brief: Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet As CFO To Support Nexalin’S Next Phase Of Growth And Strategic Initiatives